Nurexone Biologic Inc · TSXV:NRX
Nurexone Biologic — Investor Presentation (October 2024)
20 slides from Nurexone Biologic's investor presentation, October 2024
Slide 1: Where Nature Ends, NurExone Begins
NurExone biologic Where Nature Ends, NurExone Begins Transforming Regenerative Medicine Q4 2024 | Canada (TSXV: NRX) Germany (FRA: J90.F) US (OTCQB: NRXBF)
Slide 2: Disclaimer
DISCLAIMER: Contents of this presentation are provided for general information purposes only on assumptions that we believe are reasonable, we caution you that actual results and do not constitute an offer to sell or solicitation of an offer to buy any security in and developments (including our fin
Slide 3: A Transformative Approach to Regenerative Medicine
A Transformative Approach to Regenerative Medicine + = Lead asset is the Proprietary De-risked business Global patent first known ExoTherapy model with two protection across minimally invasive platform provides assets in early five patent families therapy that optionality to development which includ
Slide 4: Harnessing the Healing Power of Exosomes
Harnessing the Healing Power of Exosomes Nature’s “Guided Missiles” Target Inflamed Tissue ➢ We use exosomes as “guided missiles”, targeting specific tissues ➢ Exosomes are small particles created when stem cells proliferate and they can possess “homing” capability, targeting specific tissues and in
Slide 5: NurExone's Platform Technology - ExoTherapy
NurExone’s Platform Technology - ExoTherapy Regenerative properties and therapeutic impact. Active Pharmaceutical Exosomes ExoTherapy Nanodrug Ingredient (API) + = Exosomes are biologically- guided The company synthesizes Exosomes, after production, are nanocarriers that can deliver compounds with t
Slide 6: ExoTherapy Platform Provides Several Benefits
ExoTherapy Platform Provides Several Benefits Leveraging Exosomes as The Ultimate Drug Delivery System Minimally Invasive Crosses The Blood- Drug Administration brain-barrier Due to the natural For neuron affinity of exosomes to regeneration, rewiring inflamed or damaged and recovery tissues Cell-fr
Slide 7: Pipeline Focused on Innovation & Collaboration
Pipeline Focused on Innovation & Collaboration Studies for IND Preclinical Regulatory Program Indication Discovery (toxicity, Phase I Development Strategy efficacy) Acute Spinal ExoPTEN Cord Injury Glaucoma PNN Targeting Several - CNS Sequences Traumatic Injury Collaboration with Inteligex leverages
Slide 8: Intellectual Property Portfolio
Intellectual Property Portfolio 5 PCTs, 1 granted patent in the US PATENT FAMILY ➢ Intranasal ExoPTEN (Granted in the US and pending in Drug Administration other countries*) ➢ 2 PCTs on Production and Composition of Matter of our Exosomes and Large Scale Production exosomes ➢ 2D and 3D production to
Slide 9: Lead Clinical Indication
Lead Clinical Indication Acute Spinal Cord Injury (SCI) Approximately 50,000 new Addressable market for SCI cases of SCI are reported treatments is estimated at annually in the Western $7.5B per year, with world, with an estimated potential for growth as new ~500,000 individuals living therapies imp
Slide 10: Spinal Cord Injury Therapy - ExoPTEN Nanodrug
Spinal Cord Injury Therapy - ExoPTEN Nanodrug Proven functional recovery in preclinical animal studies This is the first known minimally invasive therapy that has successfully promoted nerve regeneration and functional recovery following complete spinal cord transection. A red and Click to watch vid
Slide 11: Spinal Cord Injury Therapy - ExoPTEN Advantages
Spinal Cord Injury Therapy - ExoPTEN Advantages Autologous Allologous Epidural Electrical Monoclonal antibody, Comparison ExoPTEN Technology Stem Cell Stem Cell Stimulation growth factors Potential to repair full transection Non immunogenic Off the shelf use Minimally nvasive 11
Slide 12: Additional Indication: Glaucoma
Additional Indication Glaucoma Glaucoma affects an Current treatments are estimated 7-10 million limited and focus on individuals in the Western preventing additional world, and globally, around damage rather than 76 million people are regenerating or repairing affected damaged nerves The market for
Slide 13: Glaucoma – ExoPTEN in Optic Nerve Recovery
Glaucoma – ExoPTEN in Optic Nerve Recovery Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals A B C Time (msec) Time (msec) Time (msec) ONC in one eye (red) with no ONC in one eye and was treated with ONC in one eye and was treated wi
Slide 14: Road Map
Road Map Clear Path towards Clinical Trials Plans for fda and ema approvals and a near future human clinical trial Q1 2023 H1 2023 Q4 2023 H1 2024 Q4 2024 H2 2025 1H 2026 1H 2026 2H 2026 Establish scaled Finalize product ODD Approval Preclinical QC/QA and IND IND submission Phase I/IIa SCI US IPO In
Slide 15: ExoPTEN is Just the Tip of the Iceberg…
ExoPTEN is Just the Tip of the Iceberg… ExoTherapy Platform Potential Leveraging Licensing and Collaboration Licensing agreements can provide additional sources of capital in areas such as … Approved or under-development drugs that cannot currently be Broad Capabilities for Market Penetration: deliv
Slide 16: Experienced Leadership Team
Experienced Leadership Team An entrepreneur and an award-winning scientist A professional track record from 1st tier global with extensive multidisciplinary international corporations and significant expertise in public experience, specializing in chemical engineering, life-science and publicly-trad
Slide 17: Seasoned Board of Directors
Seasoned Board of Directors Israel Canada Dr. Gadi Riesenfeld Dr. Lior Shaltiel Yoram Drucker Oded Orgil, LL.B. James (Jay) Richardson Founder, VP Business Development Director Chief Executive Officer & Active Chairman of the Board Dr. Riesenfeld has served on An entrepreneur and Successful Israeli
Slide 18: Expert Scientific Advisory Board
Expert Scientific Advisory Board Prof. Teodoro Forcht Prof. Gabriel Prof. Michael Dagi, MD, MPH Zeilig, MD Belkin, MD Teodoro (Teo) Forcht Dagi is a neurosurgeon Prof. Gabi Zeilig is the director of the Prof. Belkin was the founder of the Eye who serves as distinguished scholar and Department of Neu
Slide 19: NurExone Biologic Investment Summary
NurExone Biologic Investment Summary Platform with multiple shots on goal and partnership model driving uncapped opportunities ExoTherapy platform leverages the power of exosomes as a delivery & targeting mechanism providing optionality for a wide range of diseases Two clinical programs targeting ar
Slide 20: Thank You
TSXV: NRX | TSXV: NRX | OTCQB: NRXBF THANK YOU For more information please contact: Yoram Drucker, VP Strategic Operations + 972 54 4711171 yoram@nurexone.com DISCLOSURE The matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The ac
NurExone Biologic — Investor Presentation (October 2024) on 6ix